Products for Research Use Only
RegisterLogin

Brigatinib

CAT: 0804-HY-12857-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12857-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Brigatinib (AP-26113) is a highly potent, selective and orally active ALK inhibitor, with an IC50 of 0.6 nM. Brigatinib can be used for research of NSCLC[1].
CAS Number
1197953-54-0
Product Name Alternative
AP-26113
UNSPSC
12352005
Hazard Statement
H302, H317, H318, H335, H412
Target
Anaplastic lymphoma kinase (ALK)
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Brigatinib.html
Purity
99.98
Solubility
DMSO : 2 mg/mL (ultrasonic) |Ethanol : 10 mg/mL (ultrasonic; warming)
Smiles
CN1CCN(C2CCN(C3=CC=C(NC4=NC=C(Cl)C(NC5=CC=CC=C5P(C)(C)=O)=N4)C(OC)=C3)CC2)CC1
Molecular Formula
C29H39ClN7O2P
Molecular Weight
584.09
Precautions
H302, H317, H318, H335, H412
References & Citations
[1]Zhang S, et al. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016 Nov 15;22 (22) :5527-5538|[2]Huang WS, et al. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. J Med Chem. 2016 May 26;59 (10) :4948-64.|[3]Siaw JT, et al. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Oncotarget. 2016 May 17;7 (20) :29011-22
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
FC76643-01Brigatinib
GTR19263255-01Brigatinib A

Popular Products